

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61B	A2	(11) International Publication Number: WO 99/40837 (43) International Publication Date: 19 August 1999 (19.08.99)																
<p>(21) International Application Number: PCT/US99/02590 (22) International Filing Date: 5 February 1999 (05.02.99) (30) Priority Data: 60/073,882 6 February 1998 (06.02.98) US 60/077,970 13 March 1998 (13.03.98) US Not furnished 4 February 1999 (04.02.99) US</p> <p>(71) Applicant (for all designated States except US): BIOCRYSTAL LTD. [US/US]; 575 McCorkle Boulevard, Westerville, OH 43082-8888 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BABINO, Alvaro [-UY]; Rafael Eguren 3468, Montevideo CP 12.000 (UY). OSINAGA, Eduardo [-UY]; Plaza de los Olimpicos 4431, Montevideo CP 11.400 (UY). BARBERA-GUILLEM, Emilio [-US]; 1555 Picard Court, Powell, OH 43065 (US).</p> <p>(74) Agent: NELSON, Bud, M.; BioCrystal Ltd., 575 McCorkle Boulevard, Westerville, OH 43082-8888 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>																
(54) Title: COMPOSITIONS FOR DETECTING AND SURGICALLY REMOVING LYMPHOID TISSUE INVOLVED IN TUMOR PROGRESSION																		
<table border="1"> <caption>Data from Bar Chart</caption> <thead> <tr> <th>Treatment</th> <th>Ratio Test/Control (approx.)</th> </tr> </thead> <tbody> <tr> <td>T-47D alone</td> <td>12</td> </tr> <tr> <td>+Str alone</td> <td>1</td> </tr> <tr> <td>+Ab alone</td> <td>17</td> </tr> <tr> <td>Str+AbA</td> <td>38</td> </tr> <tr> <td>Str+Ab+Bik</td> <td>18</td> </tr> <tr> <td>Str+AbB</td> <td>38</td> </tr> <tr> <td>Str+FabB</td> <td>22</td> </tr> </tbody> </table>			Treatment	Ratio Test/Control (approx.)	T-47D alone	12	+Str alone	1	+Ab alone	17	Str+AbA	38	Str+Ab+Bik	18	Str+AbB	38	Str+FabB	22
Treatment	Ratio Test/Control (approx.)																	
T-47D alone	12																	
+Str alone	1																	
+Ab alone	17																	
Str+AbA	38																	
Str+Ab+Bik	18																	
Str+AbB	38																	
Str+FabB	22																	
<p>(57) Abstract</p> <p>Compositions are provided for detecting shed tumor antigen. The compositions include peptides having binding specificity for shed tumor antigen; and a detector molecule comprising a peptide, having binding specificity for shed tumor antigen, which is bound to a detectable label. The compositions may be used in a method to detect lymphoid tissues containing shed tumor antigen. Using a peptide-based detector molecule, detected in an individual having a pro-tumor immune response is the presence of lymphoid tissue which contains shed tumor antigen. Such lymphoid tissue detected as containing shed tumor antigen may then be surgically removed.</p>																		